I recall you mentioning intrathecal administration a couple years ago. Is this something Race have kept in mind while developing the new formulation?
Maybe this isn't a relevant question now, but possibly interesting. Unless I misunderstood, your comment back then alluded to bisantrene possibly crossing a leaky BBB without being administered intrathecally. Assuming I read that right, are there different levels of severity in a leaky BBB that would change required dosing? Is it a strategy that is employed with other drugs where a framework could be referenced?
I recall you mentioning intrathecal administration a couple...
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |